Lakefront's New Era: CMO Hedrick to Steer Pipeline After Ouro Deal

MECHELEN, Belgium – June 08, 2026 – Lakefront Biotherapeutics has appointed Dr. Eric Hedrick as its new Chief Medical Officer, a move that does more than just fill a C-suite seat. It signals the decisive execution of a strategic transformation that has been rapidly unfolding. Coming just four days after the company, formerly known as Galapagos, finalized its blockbuster acquisition of Ouro Medicines' assets, Hedrick's appointment is the critical human capital component in a strategy designed to build a new powerhouse in immunology and oncology. With a lucrative new pipeline and a war chest to fund further deals, bringing in a seasoned drug developer of Hedrick’s caliber is the linchpin for turning ambitious strategy into clinical reality.

A Strategic Pivot Solidified

Lakefront’s recent moves represent one of the most aggressive and well-defined corporate pivots in the European biotech sector. The company's rebranding from Galapagos in May was the first public signal of its new identity: a firm built to leverage its significant capital and deal-making expertise to acquire and advance high-potential clinical assets. The strategy was put into dramatic effect on June 4 with the acquisition of Ouro Medicines, a deal executed in partnership with Gilead Sciences.

For a total of $1.675 billion upfront, split between the two partners, Lakefront and Gilead acquired Ouro, a company that had only launched in 2025 but held a prized asset: 'gamgertamig'. This clinical-stage BCMAxCD3 T-cell engager is at the forefront of a new therapeutic paradigm known as “immune reset.” By depleting B cells and plasma cells, it aims to induce durable, drug-free remissions in patients with severe autoimmune diseases like autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). The asset comes with both Fast Track and Orphan Drug designations from the FDA, underscoring its potential and the high unmet need it addresses.

The deal structure is a masterclass in strategic alignment. Lakefront will take the lead on the agile, early-stage Phase 1/2 clinical development of 'gamgertamig', leveraging its biotech nimbleness. Gilead will then take the helm for larger, more capital-intensive registrational studies and global commercialization. In return, Lakefront secures a tiered royalty stream of 20-23% on future net sales, while also gaining three additional preclinical programs. This collaboration de-risks the lead asset's path to market while providing Lakefront with significant financial upside. Critically, the transaction leaves the company with a projected year-end cash balance of approximately €2 billion and the flexibility to deploy at least $500 million for further strategic deals, cementing its role as a formidable player in the M&A landscape.

The Veteran Hand at the Helm

An ambitious pipeline is only as good as the team tasked with developing it. With the Ouro portfolio now forming the “cornerstone of Lakefront’s R&D pipeline,” as CEO Henry Gosebruch stated, the appointment of Dr. Eric Hedrick is paramount. Hedrick, who has been with Lakefront since mid-2025 as a clinical evaluation lead, is a drug development heavyweight with a 25-year track record of bringing transformative medicines to market.

His resume reads like a highlight reel of modern oncology and hematology. During his nearly decade-long tenure at Genentech, he was involved in the clinical development of rituximab (Rituxan), the monoclonal antibody that revolutionized the treatment of non-Hodgkin's lymphoma and validated the therapeutic potential of antibody-based therapies. Later, as an executive at Pharmacyclics, he played a key role in the development of ibrutinib, the blockbuster BTK inhibitor that changed the standard of care for several B-cell cancers. His experience extends to leadership roles at Epizyme, where he focused on genetically defined cancers, and BeiGene, where he was instrumental in advancing its oncology pipeline. “Eric is a pragmatic and visionary leader,” a former colleague noted. “His strength is translating cutting-edge science into actionable clinical plans. He knows how to identify the critical path and deliver results.”

This deep expertise in hematology and B-cell biology is directly transferable to the development of 'gamgertamig', which targets the same cellular pathways, albeit in an autoimmune context. Gosebruch praised Hedrick as an “invaluable contributor,” and it’s clear his experience will be crucial. “Having a talented drug developer of Eric’s caliber and experience to guide the development of gamgertamig and our future clinical programs” is not just a corporate platitude; it is the fundamental requirement for success.

Navigating a Competitive New Frontier

Lakefront is entering a fiercely competitive but incredibly promising field. The concept of an “immune reset” is shifting the treatment goals for autoimmune disease from chronic management to potential cure. 'Gamgertamig' and its T-cell engager technology represent an “off-the-shelf” approach that offers logistical advantages over more complex CAR-T cell therapies, which are also being explored for autoimmune conditions by companies like Kyverna Therapeutics and Cartesian Therapeutics.

However, the competitive set is formidable. Other biotechs, like Cullinan Therapeutics, are also developing T-cell engagers targeting either BCMA or CD19 for autoimmune diseases. “The move by Lakefront to acquire Ouro's BCMAxCD3 T-cell engager program is highly exciting for the field,” commented an academic researcher specializing in immunology. “It offers a compelling alternative to CAR-T, potentially simplifying the treatment paradigm. Dr. Hedrick's background provides critical insights into the potential benefits and challenges of this class of drugs.”

Lakefront's competitive advantage lies in its three-pronged approach: a promising, de-risked lead asset in 'gamgertamig'; a powerful strategic alliance with Gilead for late-stage development and commercial muscle; and now, proven clinical leadership under Dr. Hedrick. “This is a bold and potentially transformative move,” stated one biotech analyst. “The acquisition immediately places them in a high-growth segment. Dr. Hedrick’s track record is precisely what Lakefront needs to navigate the competitive landscape and execute on the promise of 'gamgertamig'.”

What This Means for the Future

For Lakefront Biotherapeutics, these are not isolated events but the connected pieces of a meticulously crafted new identity. The company has shed its old skin and is rapidly building a new enterprise defined by strategic acquisitions, smart partnerships, and elite talent. The appointment of Dr. Hedrick is the final, crucial piece of the puzzle for this initial phase of its transformation. It provides the clinical and strategic stewardship necessary to advance a pipeline that could redefine treatment for debilitating autoimmune diseases.

By securing a best-in-class asset, partnering with a global giant to mitigate risk, and installing a world-class drug developer to lead the charge, Lakefront is creating a powerful engine for value creation. This is the strategy that will drive lasting competitive advantage, demonstrating how to stay ahead in a world of rapid innovation and build a biotech for the future.